Objetivo: O objetivo deste estudo foi analisar a relação do diagnóstico, à ressonância magnética, de adenomiose com endometriose. Pacientes e Métodos: Entre fevereiro de 2004 e março de 2008 foram avaliadas 152 pacientes, com diagnóstico histológico de endometriose, as quais foram separadas em dois grupos de acordo com a presença (Grupo A) ou ausência de adenomiose (Grupo B), diagnosticadas ao exame de ressonância magnética. Foram analisadas a espessura da zona juncional e a presença de cistos intramiometriais como critérios principais para diagnóstico de adenomiose. Critérios secundários como acometimento da parede posterior uterina, \"adenomiose subserosa\", zona juncional até a serosa, zona juncional indefinida e adenomiose focal também foram avaliados. Os dados obtidos pela análise do exame de imagem foram correlacionados ao quadro clínico, estadiamento, local de acometimento e a classificação histológica da endometriose. Resultados: A prevalência de adenomiose em pacientes com endometriose foi de 42,76%. Pacientes com endometriose e adenomiose, diagnosticada à ressonância magnética, apresentaram, em relação ao grupo sem adenomiose maior queixa de dismenorréia severa ou incapacitante (61,53% no Grupo A e 44,83% no Grupo B, p=0,041) e dispareunia de profundidade (64,61% no Grupo A e 41,38% no Grupo B, p=0,005), maior associação com endometriose estádio IV (50,77% no Grupo A e 33,34% no Grupo B, p=0,03), mais endometriose localizada em retossigmóide (49,23% no Grupo A e 32,18% no Grupo B, p=0,033), maior associação com endometriose indiferenciada ou mista (52,31% no Grupo A e 34,48% no Grupo B, p=0,028). As pacientes com endometriose profunda, acometendo retossigmoide, e com estádio IV, apresentaram adenomiose, correlacionada a maiores espessuras de zona juncional, predominantemente em parede posterior do útero, e relacionada ao achado radiológico de cistos intramiometriais e adenomiose subserosa (p<0,05). Conclusão: Os resultados obtidos permitem concluir que, neste estudo, observou-se correlação entre adenomiose e endometriose profunda de pior prognóstico, envolvendo principalmente o reto-sigmóide. / Objectives: The objective of this study was to analyze the relationship between endometriosis and adenomyosis diagnosed by magnetic resonance imaging (MRI). Patients and Methods: From February 2004 to March 2008, 152 patients with histological diagnosis of endometriosis were allocated in two groups, according to the presence (group A) or not (group B) of adenomyosis diagnosed by MRI. Junction zone length and myometrial cysts presence were considered the main criteria of adenomyosis diagnosis. Other aspects such as uterine posterior wall lesions, \"subserosal adenomyosis\", junction zone length until uterine serosa, undefined junction zone and focal adenomyosis were also studied. The results of MRI adenomyosis analysis were compared to endometriosis in terms of ASRM staging, sites of lesions and histological classification. Results: The prevalence of adenomyosis in patients with endometriosis was 42,76%. When compared to the group without adenomyosis, patients with endometriosis and adenomyosis, diagnosed by MRI, presented more dysmenorrhea (61,53% in group A and 44,83% in group B, p=0,041) and deep dyspareunia (64,61% in group A and 41,38% in group B, p=0,005), association with stage IV endometriosis (50,77% in group A and 33,34% in group B, p=0,03), endometriotic lesions affecting rectosigmoid (49,23% in group A and 32,18% in group B, p=0,033) and association with pure or mixed undifferentiated endometriosis (52,31% in group A and 34,48% in group B, p=0,028). Patients with lesions affecting rectosigmoid and stage IV endometriosis had an association with adenomyosis in uterine posterior wall, with thicker junction zone, myometrial cysts and \"subserosal adenomyosis\" in MRI study. Conclusions: The results of this study show correlation between adenomyosis and worse prognosis deep endometriosis, mainly involving the rectosigmoid.

Introdução: Proteínas da Superfamília do fator transformador de crescimento β (TGF-β) estão implicadas na regulação de diversas funções biológicas. Embora alguns estudos revelaram a sua presença no endométrio ectópico de portadoras de adenomiose, a sua função na etiopatogenia da doença permanece pouco conhecida. Objetivo: o estudo visa comparar a expressão imuno-histoquímica de TGF-β1 no endométrio ectópico de portadoras de adenomiose com o endométrio tópico de pacientes sem essa condição. Método: Estudo de caso-controle utilizando imuno-histoquímica em amostras uterinas (blocos de parafina) do Hospital de Clínicas de Porto Alegre. A amostra contém 28 casos de adenomiose e 21 controles. Resultados: Não encontramos associação entre tabagismo e adenomiose (P = 0,75), abortos e adenomiose (P = 0,29), gestações e adenomiose (P = 0,85), curetagens e adenomiose (P = 0,81), dor pélvica e adenomiose (P = 0,72) e presença de mioma e adenomiose (P = 0,15). Além disso encontramos relação entre sangramento uterino anormal (SUA) e adenomiose (P = 0,02) e cesarianas prévias e adenomiose (P = 0,02) . A expressão imuno-histoquímica de TGF-β1 no endométrio ectópico de portadoras de adenomiose não teve diferença significativa quando comparado com a expressão dessa proteína no endométrio tópico de pacientes sem adenomiose (P = 0,86). Conclusão: Nosso estudo foi um dos primeiros a comparar a expressão de TGF-β1 no endométrio de pacientes com e sem adenomiose. Em nossa análise não obtivemos diferença significativa entre os grupos, resultado diferente do encontrado em outros dois estudos. Mais estudos são necessários para investigar o papel da superfamília TGF no desenvolvimento e manutenção da adenomiose. / Background: Proteins of transforming growth factor β superfamily (TGF-β) are implicated in the regulation of various biological functions. Although some studies have revealed their presence in ectopic endometrium of women with adenomyosis, their role in the pathogenesis of the disease remains largely unknown. Objective: The study aims to compare the immunohistochemical expression of TGF- β1 in ectopic endometrium of women with adenomyosis with the topic endometrium of patients without this condition. Methods: Casecontrol study using immunohistochemistry in uterine samples (paraffin blocks) obteined from Hospital de Clínicas de Porto Alegre. The sample contained 28 adenomyosis cases and 21 controls. Results: We found no significant difference between smoking and adenomyosis (P = 0.75), abortions and adenomyosis (P = 0.29), pregnancies and adenomyosis (P = 0.85), curettage and adenomyosis (P = 0.81), pelvic pain and adenomyosis (P = 0.72) and presence of myoma and adenomyosis (P = 0.15). We did find a relationship between adenomyosis and abnormal uterine bleeding (AUB) (P = 0.02) and previous cesarean section and adenomyosis (P = 0.02). Immunohistochemical expression of TGF-β1 in ectopic endometrium of women with adenomyosis did not have significant difference when compared with the expression of this protein in the topic endometrium of patients without adenomyosis (P = 0.86). Conclusion: Our study was one of the first to compare the TGF-β1 expression in the endometrium of patients with and without adenomyosis. In our analysis we have not had significant difference between the groups, unlike observed in two other studies. More studies are needed to investigate the role of TGF superfamily in the development and maintenance of adenomyosis.

Objetivo: O objetivo deste estudo foi analisar a relação do diagnóstico, à ressonância magnética, de adenomiose com endometriose. Pacientes e Métodos: Entre fevereiro de 2004 e março de 2008 foram avaliadas 152 pacientes, com diagnóstico histológico de endometriose, as quais foram separadas em dois grupos de acordo com a presença (Grupo A) ou ausência de adenomiose (Grupo B), diagnosticadas ao exame de ressonância magnética. Foram analisadas a espessura da zona juncional e a presença de cistos intramiometriais como critérios principais para diagnóstico de adenomiose. Critérios secundários como acometimento da parede posterior uterina, \"adenomiose subserosa\", zona juncional até a serosa, zona juncional indefinida e adenomiose focal também foram avaliados. Os dados obtidos pela análise do exame de imagem foram correlacionados ao quadro clínico, estadiamento, local de acometimento e a classificação histológica da endometriose. Resultados: A prevalência de adenomiose em pacientes com endometriose foi de 42,76%. Pacientes com endometriose e adenomiose, diagnosticada à ressonância magnética, apresentaram, em relação ao grupo sem adenomiose maior queixa de dismenorréia severa ou incapacitante (61,53% no Grupo A e 44,83% no Grupo B, p=0,041) e dispareunia de profundidade (64,61% no Grupo A e 41,38% no Grupo B, p=0,005), maior associação com endometriose estádio IV (50,77% no Grupo A e 33,34% no Grupo B, p=0,03), mais endometriose localizada em retossigmóide (49,23% no Grupo A e 32,18% no Grupo B, p=0,033), maior associação com endometriose indiferenciada ou mista (52,31% no Grupo A e 34,48% no Grupo B, p=0,028). As pacientes com endometriose profunda, acometendo retossigmoide, e com estádio IV, apresentaram adenomiose, correlacionada a maiores espessuras de zona juncional, predominantemente em parede posterior do útero, e relacionada ao achado radiológico de cistos intramiometriais e adenomiose subserosa (p<0,05). Conclusão: Os resultados obtidos permitem concluir que, neste estudo, observou-se correlação entre adenomiose e endometriose profunda de pior prognóstico, envolvendo principalmente o reto-sigmóide. / Objectives: The objective of this study was to analyze the relationship between endometriosis and adenomyosis diagnosed by magnetic resonance imaging (MRI). Patients and Methods: From February 2004 to March 2008, 152 patients with histological diagnosis of endometriosis were allocated in two groups, according to the presence (group A) or not (group B) of adenomyosis diagnosed by MRI. Junction zone length and myometrial cysts presence were considered the main criteria of adenomyosis diagnosis. Other aspects such as uterine posterior wall lesions, \"subserosal adenomyosis\", junction zone length until uterine serosa, undefined junction zone and focal adenomyosis were also studied. The results of MRI adenomyosis analysis were compared to endometriosis in terms of ASRM staging, sites of lesions and histological classification. Results: The prevalence of adenomyosis in patients with endometriosis was 42,76%. When compared to the group without adenomyosis, patients with endometriosis and adenomyosis, diagnosed by MRI, presented more dysmenorrhea (61,53% in group A and 44,83% in group B, p=0,041) and deep dyspareunia (64,61% in group A and 41,38% in group B, p=0,005), association with stage IV endometriosis (50,77% in group A and 33,34% in group B, p=0,03), endometriotic lesions affecting rectosigmoid (49,23% in group A and 32,18% in group B, p=0,033) and association with pure or mixed undifferentiated endometriosis (52,31% in group A and 34,48% in group B, p=0,028). Patients with lesions affecting rectosigmoid and stage IV endometriosis had an association with adenomyosis in uterine posterior wall, with thicker junction zone, myometrial cysts and \"subserosal adenomyosis\" in MRI study. Conclusions: The results of this study show correlation between adenomyosis and worse prognosis deep endometriosis, mainly involving the rectosigmoid.

Introdução: Proteínas da Superfamília do fator transformador de crescimento β (TGF-β) estão implicadas na regulação de diversas funções biológicas. Embora alguns estudos revelaram a sua presença no endométrio ectópico de portadoras de adenomiose, a sua função na etiopatogenia da doença permanece pouco conhecida. Objetivo: o estudo visa comparar a expressão imuno-histoquímica de TGF-β1 no endométrio ectópico de portadoras de adenomiose com o endométrio tópico de pacientes sem essa condição. Método: Estudo de caso-controle utilizando imuno-histoquímica em amostras uterinas (blocos de parafina) do Hospital de Clínicas de Porto Alegre. A amostra contém 28 casos de adenomiose e 21 controles. Resultados: Não encontramos associação entre tabagismo e adenomiose (P = 0,75), abortos e adenomiose (P = 0,29), gestações e adenomiose (P = 0,85), curetagens e adenomiose (P = 0,81), dor pélvica e adenomiose (P = 0,72) e presença de mioma e adenomiose (P = 0,15). Além disso encontramos relação entre sangramento uterino anormal (SUA) e adenomiose (P = 0,02) e cesarianas prévias e adenomiose (P = 0,02) . A expressão imuno-histoquímica de TGF-β1 no endométrio ectópico de portadoras de adenomiose não teve diferença significativa quando comparado com a expressão dessa proteína no endométrio tópico de pacientes sem adenomiose (P = 0,86). Conclusão: Nosso estudo foi um dos primeiros a comparar a expressão de TGF-β1 no endométrio de pacientes com e sem adenomiose. Em nossa análise não obtivemos diferença significativa entre os grupos, resultado diferente do encontrado em outros dois estudos. Mais estudos são necessários para investigar o papel da superfamília TGF no desenvolvimento e manutenção da adenomiose. / Background: Proteins of transforming growth factor β superfamily (TGF-β) are implicated in the regulation of various biological functions. Although some studies have revealed their presence in ectopic endometrium of women with adenomyosis, their role in the pathogenesis of the disease remains largely unknown. Objective: The study aims to compare the immunohistochemical expression of TGF- β1 in ectopic endometrium of women with adenomyosis with the topic endometrium of patients without this condition. Methods: Casecontrol study using immunohistochemistry in uterine samples (paraffin blocks) obteined from Hospital de Clínicas de Porto Alegre. The sample contained 28 adenomyosis cases and 21 controls. Results: We found no significant difference between smoking and adenomyosis (P = 0.75), abortions and adenomyosis (P = 0.29), pregnancies and adenomyosis (P = 0.85), curettage and adenomyosis (P = 0.81), pelvic pain and adenomyosis (P = 0.72) and presence of myoma and adenomyosis (P = 0.15). We did find a relationship between adenomyosis and abnormal uterine bleeding (AUB) (P = 0.02) and previous cesarean section and adenomyosis (P = 0.02). Immunohistochemical expression of TGF-β1 in ectopic endometrium of women with adenomyosis did not have significant difference when compared with the expression of this protein in the topic endometrium of patients without adenomyosis (P = 0.86). Conclusion: Our study was one of the first to compare the TGF-β1 expression in the endometrium of patients with and without adenomyosis. In our analysis we have not had significant difference between the groups, unlike observed in two other studies. More studies are needed to investigate the role of TGF superfamily in the development and maintenance of adenomyosis.

Introdução: Proteínas da Superfamília do fator transformador de crescimento β (TGF-β) estão implicadas na regulação de diversas funções biológicas. Embora alguns estudos revelaram a sua presença no endométrio ectópico de portadoras de adenomiose, a sua função na etiopatogenia da doença permanece pouco conhecida. Objetivo: o estudo visa comparar a expressão imuno-histoquímica de TGF-β1 no endométrio ectópico de portadoras de adenomiose com o endométrio tópico de pacientes sem essa condição. Método: Estudo de caso-controle utilizando imuno-histoquímica em amostras uterinas (blocos de parafina) do Hospital de Clínicas de Porto Alegre. A amostra contém 28 casos de adenomiose e 21 controles. Resultados: Não encontramos associação entre tabagismo e adenomiose (P = 0,75), abortos e adenomiose (P = 0,29), gestações e adenomiose (P = 0,85), curetagens e adenomiose (P = 0,81), dor pélvica e adenomiose (P = 0,72) e presença de mioma e adenomiose (P = 0,15). Além disso encontramos relação entre sangramento uterino anormal (SUA) e adenomiose (P = 0,02) e cesarianas prévias e adenomiose (P = 0,02) . A expressão imuno-histoquímica de TGF-β1 no endométrio ectópico de portadoras de adenomiose não teve diferença significativa quando comparado com a expressão dessa proteína no endométrio tópico de pacientes sem adenomiose (P = 0,86). Conclusão: Nosso estudo foi um dos primeiros a comparar a expressão de TGF-β1 no endométrio de pacientes com e sem adenomiose. Em nossa análise não obtivemos diferença significativa entre os grupos, resultado diferente do encontrado em outros dois estudos. Mais estudos são necessários para investigar o papel da superfamília TGF no desenvolvimento e manutenção da adenomiose. / Background: Proteins of transforming growth factor β superfamily (TGF-β) are implicated in the regulation of various biological functions. Although some studies have revealed their presence in ectopic endometrium of women with adenomyosis, their role in the pathogenesis of the disease remains largely unknown. Objective: The study aims to compare the immunohistochemical expression of TGF- β1 in ectopic endometrium of women with adenomyosis with the topic endometrium of patients without this condition. Methods: Casecontrol study using immunohistochemistry in uterine samples (paraffin blocks) obteined from Hospital de Clínicas de Porto Alegre. The sample contained 28 adenomyosis cases and 21 controls. Results: We found no significant difference between smoking and adenomyosis (P = 0.75), abortions and adenomyosis (P = 0.29), pregnancies and adenomyosis (P = 0.85), curettage and adenomyosis (P = 0.81), pelvic pain and adenomyosis (P = 0.72) and presence of myoma and adenomyosis (P = 0.15). We did find a relationship between adenomyosis and abnormal uterine bleeding (AUB) (P = 0.02) and previous cesarean section and adenomyosis (P = 0.02). Immunohistochemical expression of TGF-β1 in ectopic endometrium of women with adenomyosis did not have significant difference when compared with the expression of this protein in the topic endometrium of patients without adenomyosis (P = 0.86). Conclusion: Our study was one of the first to compare the TGF-β1 expression in the endometrium of patients with and without adenomyosis. In our analysis we have not had significant difference between the groups, unlike observed in two other studies. More studies are needed to investigate the role of TGF superfamily in the development and maintenance of adenomyosis.

L’adénomyose est une pathologie chronique bénigne de l’utérus caractérisée par une infiltration du myomètre par du tissu endométrial composé de glandes et de stroma avec une hypertrophie et une hyperplasie des cellules musculaires lisses adjacentes. Cette maladie fréquente de la femme en âge de procréer cause des symptômes invalidants comme des dysménorrhées, des saignements utérins anormaux et une infertilité. L’adénomyose utérine est souvent associée à d’autres pathologies gynécologiques bénignes œstrogéno-dépendantes comme les léiomyomes utérins et l’endométriose. Les options thérapeutiques médicamenteuses sont purement symptomatiques et non-curatives et l’adénomyose reste une cause majeure d’hystérectomie. Les mécanismes physiopathologiques qui aboutissent au développement de l’adénomyose sont probablement multifactoriels et ne sont que partiellement compris actuellement. Selon la théorie la plus communément admise, l’adénomyose trouve son origine dans la couche basale de l’endomètre avec une invagination de cellules entre les faisceaux musculaires et/ou le long de vaisseaux lymphatiques. De multiples facteurs pourraient être impliqués dans l’initiation de cette invasion, notamment une résistance à l’action de la progestérone, une production intra-lésionnelle d’œstrogènes par activation de l’aromatase, des anomalies myométriales prédisposant à l’invasion, des lésions tissulaires induites par la grossesse, l’accouchement, le dyspéristaltisme utérin ou iatrogènes et des anomalies de l’endomètre le prédisposant à l’invasion. Dans un premier temps nous détaillons, dans un article de revue, les traitements médicamenteux actuellement utilisés pour traiter les symptômes causés par l’adénomyose et discutons les mécanismes physiopathologiques qui pourraient être la cible de nouveaux traitements médicamenteux. Ensuite, nous exposons les résultats de l’étude in vitro des voies de signalisation cellulaires des mitogen-activated protein kinases (MAPKs) et phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin (PI3K/mTOR/Akt) dans les cellules musculaires lisses utérines issues de femmes avec de l’adénomyose et de témoins sans adénomyose. Nous montrons une augmentation de la prolifération des cellules myométriales avec une activation in vitro de la voie MAPK/ERK chez les femmes avec de l’adénomyose en comparaison avec les témoins. L’activation de la voie PI3K/mTOR/Akt n’est pas significativement différente. La production de dérivés réactifs de l’oxygène et leurs voies de détoxification ne sont pas différentes dans les cellules myométriales de femmes avec de l’adénomyose et celles de témoins, ce qui suggère une activation de la voie des MAPK/ERK indépendante des dérivés réactifs de l’oxygène. Nos résultats montrent que des inhibiteurs des protéines kinases et le rapanalogue temsirolimus contrôlent la prolifération des cellules myométriales in vitro, ce qui suggère une implication des voies de signalisation MAPK/ERK et PI3K/mTOR/Akt dans la prolifération des cellules musculaires lisses dans l’adénomyose et les léiomyomes. Finalement, nous avons étudié l’ostéopontine comme biomarqueur sérique dans une cohorte de femmes en âge de procréer opérées pour des pathologies gynécologiques bénignes. La présence d’endométriose a été déterminée chirurgicalement et les lésions endométriosiques ont été confirmées histologiquement et classées en lésions superficielles, endométriomes ou lésions invasives profondes. La présence d’adénomyose a été déterminée par imagerie par résonance magnétique préopératoire et deux types d’adénomyose ont été caractérisés : l’adénomyose diffuse, l’adénomyose focale avec ou sans lésions diffuses associées. L’ostéopontine sérique est diminuée en cas d’adénomyose focale et de lésions d’endométriose profonde en comparaison avec des témoins sains et augmentée dans l’endométriose superficielle en comparaison avec l’endométriose profonde. (...) / Adenomyosis is chronic benign uterine disease characterized by myometrial infiltration by endometrial tissue – both glands and stroma – with hypertrophy and hyperplasia of surrounding smooth muscle cells. This frequent disease occurring in reproductive age women causes invalidating symptoms such as dysmenorrhoea, abnormal uterine bleeding and infertility. Adenomyosis is frequently associated with other estrogen-dependant gynaecologic diseases such as uterine leiomyomas and endometriosis. Medical treatments are non-curative and act purely by alleviating symptoms and adenomyosis remains a major cause of hysterectomy. Physiopathological mechanisms underlying the disease are probably multifactorial and currently not fully elucidated. According to the most widely accepted theory adenomyosis originates from the basal layer of the endometrium which invaginates between smooth muscle cell bundles and/or along lymphatic vessels. Multiple factors could be implicated in triggering this invasion, amongst others resistance to progesterone, intra-lesional production of estrogens through aromatase activation, myometrial anomalies predisposing to invasion, tissue lesions induced by pregnancy, labour, uterine dysperistaltism or iatrogenic and endometrial anomalies predisposing to invasion. First, in a clinical review article, we detail current medical therapies used to alleviate adenomyosis-associated symptoms and discuss physiopathological mechanisms that could be targets for novel medical treatments. We then describe an in vitro study on the activation of the mitogen-activated protein kinases (MAPKs) and phosphatidylinositol three kinase/mammalian target of rapamycin/Akt (PI3K/mTOR/Akt) signalling pathways in uterine smooth muscle cells derived from women with adenomyosis and from adenomyosis-free controls. We show an increased proliferation of uterine smooth muscle cells related to the in vitro activation of the MAPK/ERK pathway in women with adenomyosis compared to controls. The activation of PI3K/mTOR/Akt was not significantly different. The production of reactive oxygen species and their detoxification enzymes were not different in uterine smooth muscle cells of women with adenomyosis compared to controls suggesting a reactive oxygen species independent activation of the MAPK/ERK pathway. Our results also show that inhibitors of protein kinases and the rapanalogue temsirolimus control the in vitro proliferation of uterine smooth muscle cells suggesting an implication of both MAPK/ERK and PI3K/mTOR/Akt in the proliferation of uterine smooth muscle cells in adenomyosis and leiomyomas. Finally, we studied osteopontin as a serum biomarker in a cohort of reproductive-age women undergoing surgery for benign gynaecological conditions. The presence of endometriosis was determined surgically and endometriosis lesions were confirmed histologically and classified into superficial lesions, endometriomas and deep infiltrating lesions. The presence of adenomyosis was determined by magnetic resonance imaging before surgery and women were classified according to two types of adenomyosis: diffuse adenomyosis, focal adenomyosis with or without associated diffuse lesions. Osteopontin levels were decreased in case of focal adenomyosis and deep infiltrating endometriosis compared to disease-free women and increased in superficial endometriosis compared to deep infiltrating endometriosis. Osteopontin, a secreted glycoprotein implicated in inflammation and in tumor-metastasis, is not a biomarker of disease severity in endometriosis and adenomyosis but could reflect events implicated in peritoneal dissemination of endometriosis lesions.

<p>Uvod: Infertilitet pogađa 10-15% parova reproduktivnog doba. Vanetesna oplodnja (VTO) je najefikasniji vid tret-mana infertiliteta, ali uprkos značajnom napretku stopa uspeha VTO u proseku iznosi oko 30% po ciklusu. Glavnim razlogom neuspeha smatra se neadekvatan kvalitet embriona, dok se pretpostavlja da u 10-20% slučajeva razlog neuspeha leži u neadekvatnoj receptivnosti uterusa. Na osnovu inicijalnih istraživanja histeroskopija, koja predstvalja zlatni standard u dijagnostici i tretmanu patologije kavuma uterusa, se često izvodi u svakodnevnoj kliničkoj praksi kako bi se povećala uspe&scaron;nost VTO. Uprkos &scaron;irokoj primeni i dalje ne postoji dovoljno kvalitetnih dokaza o realnoj ulozi histeroskopije na ishod VTO kako kod patolo&scaron;kih stanja kavuma tako i rutinski, pre prvog ili rekurentnog poku&scaron;aja VTO. Cilj disertacije bio je da se utvrdi uticaj sprovođenja histeroskopije na ishod VTO, ustanovi učestalost prethodno neprepoznate patologije kavuma uterusa, kao i da se ispitaju stavovi pacijenata o primeni rutinske histeroskopije pred VTO. Materijal i metode: Istraživanje je sprovedeno u Kliničkom centru Vojvodine, u formi prospektivne studije u dve sukcesivne etape od 01.01.2015. do 01.04.2017. U prvoj etapi poređen je ishod VTO kod pacijentkinja kojima pred postupak VTO nije sprovedena histeroskopija (Grupa A), pacijentkinja kod kojih je dobijen uredan nalaz histeroskopije pred postupak VTO (Grupa B) i pacijentkinja gde je pred postupak VTO dobijen patolo&scaron;ki nalaz kavuma na histeroskopiji koji je u istom aktu tertian (Grupa C). Druga etapa istraživanja predstavljala je randomiziranu kontrolisanu studiju (RCT &ndash; randomised controlled trial). Nakon verifikacije urednog ultrazvučnog nalaza pred prvi postupak VTO, pacijentkinje su randomizirane u Grupu A2 kojima pred postupak VTO nije sprovedena histeroskopija i Grupu B2 kojima je pred postupak VTO sprovedena rutinska histeroskopija. Statistička analiza sprovedena je upotrebom odgovarajućeg softvera (JMP Ver. 9). Poređeni su podaci o osnovnim karakteristikama pacijenata, toka i ishoda ciklusa VTO. Primarni parametar ishoda bila je stopa kliničke trudnoće po embriotransferu. Pored analize ishoda primarno konstruisanih grupa, urađena je analiza i naknadno konstruisanih subgrupa, kao i predikcioni model uspeha VTO baziran na logističkoj regresiji. Rezultati: Studija je uključila 253 pacijentkinje (52 pacijentkinja iz Grupe A, 50 iz Grupe B, 50 iz Grupe C, 51 iz Grupe A2 i 50 iz Grupe B2). Nije postojala statistički značajna razlika u karakteristikama pacijentkinja, parametrima ovarijalne rezerve, broju dobijenih jajnih ćelija ni drugim parametrima toka postupka VTO među posmatranim grupama. U prvoj etapi istraživanja dobijena je statistički značajno (p=0,013) veća stopa kliničkih trudnoća kod pacijentkinja kojima je pred postupak VTO sprovedena histeroskopija - 50 % za Grupu B i 42% za grupu C u odnosu na 30,77% kod pacijentkinja bez histeroskopije (Grupa A), bez statistički značajne razlike među histeroskopskim grupama. U drugoj etapi istraživanja stopa kliničkih trudnoća prilikom upotrebe rutinske histeroskopije pred prvu VTO (Grupa B2) iznosila je 46% naspram 31,37% kod pacijentkinja bez histeroskopije pred prvu VTO (Grupa A2), iako uočena razlika nije dostigla statističku značajnost (p =0,089), uz relativan rizik (RR) za ostvarivanje kliničke trudnoće nakon primene histeoskopije uiznosio od 1,47 (95% CI 0,88-2,43) (p=0,13). Analizon subgrupa kod 100 pacijentkinja sa rutinski sprovedenom histeroskopijom pred VTO i 103 pacijentkinje bez histeroskopije pred VTO, dobijena je statistički značajnao veća stopa kliničkih trudnoća (48% naspram 31,07%, istim redom), uz RR od 1,54 (95% CI 1,08-2,20) (p=0,013), kao i stopa tekućih trudnoća od RR 1,49 (CI 1,01-2,19) (p= 0,039). Analiza ukupnog uticaja izvođenja histeroskopije pred VTO dobila je statistički značanjno veću stopu kliničkih trudnoća po ET za grupu histeroskopije uz RR 1,48 (CI 1,06-2,07) (p=0,017). Histeroskopijom je nakon urednog ultrazvučnog nalaza ustanovljeno postojanje patolo&scaron;kog nalaza kod 34,65% pacijenata i to 22,7% major patologije i 11,88% minor patologije kavuma. Nije postojala statistički značajna razlika u uspehu VTO u odnosu na sam nalaz histeroskopije. 98,67% pacijenata podržalo je rutinsku upotrebu histeroskopije pred prvi postupak VTO, dok je 83% pacijenata podržavlo rutinsku upotrebu histeroskopije pred svaki postupak VTO. U finalnom predikcionom modelu se uz AUC od 0,748 jedino postojanje visokokvalitetnog embriona uz odnos &scaron;ansi (OR) 7,91 (95% CI 1,80-56,06; p=0,0047), transfer blastociste uz OR 3,80 (95% CI 1,90-7,98; p=0,0001) i izvođenje histeroskopije pred VTO uz OR 2,13 (95% CI 1,14-4,08, p=0,0169) pokazalo statistički značajnim prediktorima trudnoće. Diskusija: Studija je dobila pozitivan uticaj histeroskopije na ishod postupka VTO, iskazan pre svega povećanjem stope kliničkih trudnoća nakon sprovođenja histeroskopije (bilo da je na histeroskopiji nađen uredan ili patolo&scaron;ki nalaz). Dodatna prednost histeroskopije predstavljala je i i detekcija prethodno nepropoznate patologije kavuma. Umeren efekat na ukupno pobolj&scaron;anje stope kliničkih trudnoća prilikom rutinskog sprovođenja histeroskopije pred prvu VTO, koji je statističku značajnost dostigao tek analizom subgrupa u skladu je sa nalazima novijih dobro dizajniranih studija koji donekle limitiraju nekritičku upotrebu histeroskopije. Biolo&scaron;ko obja&scaron;njenje potencijalnog pozitivnog uticaja histeroskopije najverovatnije leži u detekciji i tretmanu prethodno nepropoznate patologije kavuma, olak&scaron;avanju procedure embriotransfera, kao i humoralnim i molekularnim promenama koje nastaju u endometrijumu kao posledica odgovarajuće histeroskopske traume a koji su u dosa&scaron;anjim istraživanjima apostrofirani kao faktori koji mogu povećati receptivnost uterusa. Zaključak: Histeroskopija je efikasna, bezbedna i visoko prihvatljiva procedura koja dovodi do povećanja uspeha VTO u standardnim kliničkim indikacijama (prethodnog neuspelog postupka VTO i sumnje na patolo&scaron;ki nalaz kavuma uterusa) bilo da se na samoj histeroskopiji nađe uredan ili patolo&scaron;ki nalaz. Rutinska primena histeroskopije pred prvi postupak VTO se na osnovu rezultata studije ne može smatrati apsolutno opravdanom usled statistički nedovoljno značajnog povećanja stope kliničke trudnoće. Uzev&scaron;i u obzir visoku prihvatljivost od strane pacijenata i najverovatniji pozitivan efekat na stopu trudnoće primena rutinske histeroskopije pred prvu VTO bila bi opravdana ukoliko se implementira koncept ambulantne histeroskopije.</p> / <p>Introduction: Infertility affects 10-15% of all couples. In vitro fertilisation (IVF) is the most effective method of infertility treatment, but despite a significant improvement, success rate of IVF is still around 30% per cycle. The main reason for the IVF failure is inadequate embryo quality, but in 10-20% of cases the cause of IVF failure lies in impaired uterine receptivity. Based on earlier studies hysteroscopy, gold standard in the diagnosis and treatment of uterine cavity pathology, is often performed to increase IVF success. Despite its wide use, there is lack of high quality evidence regarding real contribution of hysteroscopy on IVF outcome in situations of uterine cavity pathology or routinely prior to first IVF or after recurrent implantation failure. The aim of this dissertation was to determine the influence of performing hysteroscopy on IVF outcome, as well as the incidence of previously unrecognized uterine pathology, and to examine patient&#39;s attitudes about performing routine hysteroscopy prior to IVF. Material and methods: The research was conducted in a prospective manner in two successive stages at Clinical Center of Vojvodina from 01.01.2015. until 01.04.2017. During first stage of the study IVF outcome was compared between patients who did not have a hysteroscopy prior to IVF (group A), patients with normal hysteroscopic finding prior to the IVF (Group B) and patients with abnormal hysteroscopic findings prior to IVF which was treated at the same time (Group C). The second stage of the study was a randomized controlled trial (RCT). After verification of normal ultrasound findings prior to the first IVF, patients were randomized to group A2 in who me hysteroscopy was not performed and group B2 who had routine hysteroscopy prior to first IVF. Statistical analysis was carried out using the appropriate statistical software (JMP Ver. 9). Patient characteristics, course and outcome of IVF cycle were compared between groups. The primary outcome was clinical pregnancy rate (CPR) per embryotransfer. In addition to analyzing the IVF outcomes in primarily defined groups, subgroup analysis was also performed, as well as IVF success pre-diction model based on logistic regression. Results: The study included 253 patients (52 patients in Group A, 50 in Group B, 50 in Group C, 51 in Group A2 and 50 in Group B2). There was no statistically significant difference in patient characteristics, ovarian reserve parameters, number of retrieved oocytes, or other relevant parameters of IVF course between the observed groups. In the first stage of the study there was statistically significant (p = 0.013) higher clinical pregnancy rate in patients who had a hysteroscopy before IVF - 50% for Group B and 42% for group C versus 30,77 % in patients without hysteroscopy before IVF (Group A), without statistically significant difference between hysteroscopic groups. In the second stage of the study, routine hysteroscopy prior to first IVF (Group B2) led to clinical pregnancy rate 46% versus 31.37% in patients without hysteroscopy prior to first IVF (Group A2), although without statistical significance (p = 0.089. Relative risk (RR) for achieving clinical pregnancy after performing hysteroscopy was 1.47 (95% CI 0.88-2.43) (p = 0.13). Subgroup analysis of 100 patients with routinely performed hysteroscopy before IVF and 103 patients without hysteroscopy prior to the IVF showed statistically significant higher rates of clinical pregnancies (48% versus 31.07%, in the same order), with RR of 1.54 (95% CI 1.08-2.20), (p = 0.013), and for ongoing pregnancies RR was 1.49 (95% CI 1.01-2.19) (p = 0.039). Overall effect of performing hysteroscopy prior to IVF resulted in a statistically significant increase in the clinical pregnancy with RR 1.48 (95% CI 1.06-2.07) (p = 0.017). After normal ultrasound finding hysteroscopy revealed 34.65% of pathological finding, 22.7% of major and 11.88% of minor pathology of the cavity). There was no statistically significant difference in IVF outcome based on hysteroscopy findings. 98.67% of patients supported the routine use of hysteroscopy before the first IVF procedure, while 83% of patients supported the routine use of the hysteroscopy before every IVF procedure. In the final prediction model, with the AUC of 0.748, only the presence of high quality embryos with odds ratio (OR) 7,91 (95% CI 1,80-56,06; p=0,0047), blastocyst transfer with OR 3,80 (95% CI 1,90-7,98; p=0,0001) and performing hysteroscopy prior to IVF with OR 2,13 (95% CI 1,14-4,08, p=0,0169) proved to be statistically significant predictors of pregnancy. Discussion: The study shoved a positive influence of hysteroscopy on the IVF outcome by increasing clinical pregnancy rate after performing hysteroscopy (whether hysteroscopy revealed normal or pathological finding). Additional benefit of hysteroscopy was detection of previously unrecognized uterine pathology. A moderate effect on the overall improvement in clinical pregnancy rate with use of routine hysteroscopy, which reached statistical significance only by subgroup analysis, is in line with findings of recent well designed studies that somewhat limit the noncritical use of hysteroscopy. A biological explanation of the potential positive effect of hysteroscopy is most likely due to detection and treatment of the previously unrecognized uterine pathology, facilitating embryotransfer procedure, as well as the humoral and molecular changes that occur in the endometrium as a consequence of the hysteroscopic trauma. Those changes were hypothesized as factors that can increase uterine receptivity by numerous research. Conclusion: Hysteroscopy is an effective, safe and highly acceptable procedure that increases IVF success when performed for accepted clinical indications (previous IVF failures, pathological findings of uterine cavity), whether hysteroscopy reveals normal or pathological finding. The routine use of hysteroscopy prior to first IVF based on this study can not be considered justified since increase in clinical pregnancy rate did not reach statistical significance. Given the high acceptance of this concept by the patients and moderate but probable positive effect on IVF outcome, implementation of routine hysteroscopy prior to first VTO would be justified only in office hysteroscopy setting.</p>